ZW4488A1 - Steroid 5-alpha-reductase inhibitors - Google Patents

Steroid 5-alpha-reductase inhibitors

Info

Publication number
ZW4488A1
ZW4488A1 ZW44/88A ZW4488A ZW4488A1 ZW 4488 A1 ZW4488 A1 ZW 4488A1 ZW 44/88 A ZW44/88 A ZW 44/88A ZW 4488 A ZW4488 A ZW 4488A ZW 4488 A1 ZW4488 A1 ZW 4488A1
Authority
ZW
Zimbabwe
Prior art keywords
steroid
alpha
reductase inhibitors
reductase
inhibitors
Prior art date
Application number
ZW44/88A
Other languages
English (en)
Inventor
Alan Holt Dennis
John Kowalski Conrad
Alan Levy Mark
Walter Metcalf Brian
Marie Tickner Anne
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26720806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZW4488(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of ZW4488A1 publication Critical patent/ZW4488A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0095—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 carbon in position 21 is part of carboxylic group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZW44/88A 1987-04-29 1988-04-25 Steroid 5-alpha-reductase inhibitors ZW4488A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4377387A 1987-04-29 1987-04-29
US07/127,147 US4910226A (en) 1987-04-29 1987-12-01 Steroid 5-alpha-reductase inhibitors

Publications (1)

Publication Number Publication Date
ZW4488A1 true ZW4488A1 (en) 1988-09-21

Family

ID=26720806

Family Applications (1)

Application Number Title Priority Date Filing Date
ZW44/88A ZW4488A1 (en) 1987-04-29 1988-04-25 Steroid 5-alpha-reductase inhibitors

Country Status (23)

Country Link
US (1) US4910226A (enExample)
EP (1) EP0289327B1 (enExample)
JP (1) JPH0745511B2 (enExample)
KR (1) KR0131207B1 (enExample)
CN (2) CN1026236C (enExample)
AU (1) AU615439B2 (enExample)
CA (1) CA1327352C (enExample)
CY (1) CY1822A (enExample)
DE (1) DE3866938D1 (enExample)
DK (1) DK175522B1 (enExample)
ES (1) ES2039278T3 (enExample)
FI (1) FI95712C (enExample)
GR (1) GR3003768T3 (enExample)
HK (1) HK22695A (enExample)
HU (2) HU201956B (enExample)
IE (1) IE60545B1 (enExample)
IL (1) IL86185A (enExample)
MY (1) MY103518A (enExample)
NO (1) NO172586C (enExample)
NZ (1) NZ224377A (enExample)
PH (1) PH25963A (enExample)
PT (1) PT87380B (enExample)
ZW (1) ZW4488A1 (enExample)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571817A (en) * 1984-02-27 1996-11-05 Merck & Co., Inc. Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
US5138063A (en) * 1984-02-27 1992-08-11 Merck & Co., Inc. 17β-methoxycarbonyl-4-aza-androsten-1-en-3-ones
US5041433A (en) * 1987-04-29 1991-08-20 Smithkline Beecham Corporation 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase
CA1331457C (en) * 1988-05-25 1994-08-16 Dennis Alan Holt Aromatic steroid 5-–-reductase inhibitors
US5026882A (en) * 1988-12-23 1991-06-25 Smithkline Beecham Corporation Phosphinic acid substituted steroids as inhibitors of steroid 5α-reductase
US4970205A (en) * 1988-12-23 1990-11-13 Smithkline Beecham Corporation Sulfonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4937237A (en) * 1988-12-23 1990-06-26 Smithkline Beckman Corporation Phosphinic acid substituted aromatic steroids as inhibitors of steroid 5-60 -reductase
US4946834A (en) * 1988-12-23 1990-08-07 Smithkline Beecham Corporation Phosphonic acid substituted steroids as steroid 5α-reductase inhibitors
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
US4970204A (en) * 1989-08-23 1990-11-13 Smithkline Beecham Corporation 3-substituted nitro-steroid derivatives as 5-α-reductase inhibitors
US5032586A (en) * 1989-08-24 1991-07-16 Smithkline Beecham Corporation 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase
US5100917A (en) * 1989-12-29 1992-03-31 Merrell Dow Pharmaceuticals Inc. Novel a-nor-steroid-3-carboxylic acid derivatives
US5137882A (en) * 1990-06-11 1992-08-11 Holt Dennis A Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors
US5098908A (en) * 1990-06-20 1992-03-24 Merck & Co., Inc. 17β-hydroxybenzoyl-4-aza-5α-androst-1-en-3-ones as testosterone reductase inhibitors
US5162332A (en) * 1990-06-20 1992-11-10 Merck & Co., Inc. Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
US5061802A (en) * 1990-06-20 1991-10-29 Merck & Co. Inc. 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
US5151430A (en) * 1990-06-20 1992-09-29 Merck & Co., Inc. Specific 17β-thiobenzoyl-4-aza-5α-androst-1-en-3-ones as antiandrogen agents
US5300294A (en) * 1990-06-27 1994-04-05 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
US5075450A (en) * 1990-06-28 1991-12-24 Merck & Co., Inc. Intermediates in the synthesis of 17β-acyl-3-carboxy-androsta-3,5-dienes
US5091380A (en) * 1990-06-28 1992-02-25 Merck & Co., Inc. N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors
CA2045865A1 (en) * 1990-06-28 1991-12-29 Gary H. Rasmusson Intermediates on the synthesis of 17 beta-acyl-3-carboxy-androsta-3,5-dienes
CA2045866A1 (en) * 1990-06-28 1991-12-29 Gary H. Rasmusson 17-beta-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5 alpha-reductase inhibitors
NZ241979A (en) * 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
IT1259419B (it) * 1991-05-24 1996-03-18 Erba Carlo Spa Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi
US5196411A (en) * 1991-08-16 1993-03-23 Merck & Co., Inc. 17β-acyl-3-carboxy-androsta-3,5-dienes as testosterone 5α-reductase inhibitors
NZ245504A (en) * 1991-12-20 1995-08-28 Hoechst Ag Bile acid derivatives containing an ethylenically unsaturated grouping
GB9206413D0 (en) * 1992-03-24 1992-05-06 Smithkline Beecham Corp N-t-butyl-androst-3,5-diene-17b-carboxamide-3-carboxylic acid polymorph a
GB9206414D0 (en) * 1992-03-24 1992-05-06 Smithkline Beecham Corp N-t-butyl-androst-3,5-diene-17b-carboxamide-3-carboxylic acid polymorph b
DK0567271T3 (da) * 1992-04-20 1998-02-16 Sankyo Co Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf
US5698720A (en) * 1992-04-20 1997-12-16 Sankyo Company, Limited Steroid derivatives
ATE198601T1 (de) * 1992-05-20 2001-01-15 Merck & Co Inc Ester derivate von 4-aza-steroiden
WO1993023048A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 4-azasteroid 5-alpha-reductase inhibitors
US5237064A (en) * 1992-05-20 1993-08-17 Merck & Co., Inc. Process for producing 7β-substituted-aza-5αandrostan-3-ones
DE69313114T2 (de) * 1992-05-20 1998-03-19 Merck & Co Inc NEUE DELTA-17 UND DELTA-20 UNGESÄTIGTE UND GESATIGTE 17--g(b)-SUBSTITUIERTE-4-AZA-5-g(a)-ANDROSTAN-3-ON VERBINDUNGEN ALS INHIBITOREN VON 5-ALPHA-REDUCTASE
WO1993023040A1 (en) * 1992-05-20 1993-11-25 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
CA2135057A1 (en) * 1992-05-20 1993-11-25 Bruce E. Witzel 17-amino substituted 4-azasteroid 5a-reductase inhibitors
SK137994A3 (en) * 1992-05-20 1995-04-12 Merck & Co Inc 7-beta-substituted-4-aza-5-alpha-cholestan-ons their using for production of pharmaceutical agent and pharmaceutical agent containing them
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9213901D0 (en) * 1992-06-30 1992-08-12 Smithkline Beecham Corp Compounds
US5324734A (en) * 1992-09-15 1994-06-28 Merck & Co., Inc. Oxidization metabolites of 5-α-23-methyl-4-aza-21-nor-chol-1-ene-3, 20-dione
US5278159A (en) * 1992-10-06 1994-01-11 Merck & Co., Inc. Aryl ester derivatives of 3-oxo-4-aza-androstane 17-β-carboxylates as 5-α-reductase inhibitors
IL107611A0 (en) * 1992-11-18 1994-02-27 Smithkline Beecham Corp Steroid compounds and pharmaceutical compositions containing them
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994021614A1 (en) * 1993-03-24 1994-09-29 Merck & Co., Inc. SUBSTITUTED 3-PHENANTHRIDINONE DERIVATIVES AS 5α-REDUCTASE INHIBITORS
AU6427094A (en) * 1993-04-02 1994-10-24 Ciba-Geigy Ag 17beta -substituted androsta-3,5-diene derivatives
CA2165077A1 (en) * 1993-06-28 1995-01-05 Philippe L. Durette 4-aza-pregnane 5.alpha.-reductase isozyme 1 inhibitors
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
GB2282324A (en) * 1993-10-01 1995-04-05 Merck & Co Inc 17ß-Acyl-3-Carboxy-Androsta-3,5-dienes as anti-androgenic alopecia agents
US5637310A (en) * 1993-12-20 1997-06-10 Smithkline Beecham Corporation Method of treating prostatic adenocarcinoma
FR2724174B1 (fr) * 1994-09-06 1997-01-17 Roussel Uclaf Procede de preparation d'un derive steroide 17beta-carboxy et nouveaux intermediaires
EP0784627A4 (en) * 1994-10-05 1998-05-06 Smithkline Beecham Corp PROCESS FOR THE PREPARATION OF ANDROSTA-3,5-DIENE-3-CARBOXYLIC ACIDS WITH 17 BETA SUBSTITUTION
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US6372712B1 (en) 1998-05-22 2002-04-16 The Board Of Trustees Of The Leland Stanford Jr. University Synthetic bifunctional molecules containing a drug moiety and presenter protein ligand
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1422234A3 (en) * 1999-03-23 2010-12-08 Harbor BioSciences, Inc. Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone
ES2215631T3 (es) * 1999-03-23 2004-10-16 Hollis-Eden Pharmaceuticals Inc. Hemihidrato de 16alfa-bromoepiandrosterona.
JP2000309599A (ja) 1999-04-13 2000-11-07 Kyowa Hakko Kogyo Co Ltd エストラ−１，３，５（１０），１６−テトラエン誘導体
CA2522784C (en) 2003-04-01 2012-06-19 Hollis-Eden Pharmaceuticals, Inc. Antiandrogens with marginal agonist activity and methods of use
US7326717B2 (en) * 2003-05-06 2008-02-05 L'oreal Pyrimidine n-oxide compounds for stimulating the growth of keratin fibers and/or reducing loss thereof
US20060193804A1 (en) * 2005-02-24 2006-08-31 L'oreal Haircare use of cyclic amine derivatives
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
CN100355772C (zh) * 2005-12-28 2007-12-19 天津大学 具有5α－还原酶抑制活性的甾体化合物及其制备方法
EP1897533A1 (en) * 2006-09-08 2008-03-12 Revotar Biopharmaceuticals AG Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha -D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
FR2929118B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association de madecassoside et/ou de terminoloside et d'une arginine pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
FR2929117B1 (fr) 2008-03-28 2010-05-07 Oreal Utilisation de l'association du 2,4-diaminopyrimidine 3-n-oxyde et du madecassosside et/ou du terminoloside pour induire et/ou stimuler la croissance de ces fibres keratiniques humaines et/ou freiner leur chute
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
FR2949052B1 (fr) 2009-08-13 2015-03-27 Oreal Procede de traitement cosmetique du cuir chevelu.
CA2870666A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
EP3226859B1 (en) 2014-12-05 2025-03-26 Case Western Reserve University Akr1a1 inhibitors for use in lowering cholesterol and modulate s-nitrosylation
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury
CN111362999B (zh) * 2020-03-16 2022-03-29 江苏联环药业股份有限公司 一种爱普列特杂质及其制备方法和应用
CR20220654A (es) 2020-05-20 2023-08-24 Rodeo Therapeutics Corp Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
CN116606340A (zh) * 2022-10-14 2023-08-18 上海醇健实业发展有限公司 一种甾体化合物及其制备方法、其用途和其药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3129233A (en) * 1961-08-28 1964-04-14 American Home Prod 17beta-acetoxy-3-chloro-3, 5-androstadiene
US3530170A (en) * 1968-09-04 1970-09-22 Du Pont Selected 2-acyl-a-nor-5alpha-androstane derivatives
JPS539216B2 (enExample) * 1973-11-28 1978-04-04
US4088760A (en) * 1976-06-23 1978-05-09 Richardson-Merrell Inc. Testosterone 5α-reductase inhibitors
US4191759A (en) * 1978-04-13 1980-03-04 Merck & Co., Inc. N-substituted-17β-carbamoylandrost-4-en-3-one 5α reductase inhibitors
US4317817A (en) * 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors

Also Published As

Publication number Publication date
AU1516588A (en) 1988-11-03
FI882007A0 (fi) 1988-04-28
FI95712B (fi) 1995-11-30
NO881857D0 (no) 1988-04-28
DE3866938D1 (de) 1992-01-30
NO172586C (no) 1993-08-11
NO172586B (no) 1993-05-03
IL86185A (en) 1996-06-18
FI95712C (fi) 1996-03-11
NO881857L (no) 1988-10-31
MY103518A (en) 1993-07-31
PH25963A (en) 1992-01-13
DK175522B1 (da) 2004-11-22
AU615439B2 (en) 1991-10-03
PT87380B (pt) 1992-08-31
GR3003768T3 (enExample) 1993-03-16
HU201956B (en) 1991-01-28
IE60545B1 (en) 1994-07-27
CA1327352C (en) 1994-03-01
DK226888D0 (da) 1988-04-26
FI882007L (fi) 1988-10-30
CN1079747A (zh) 1993-12-22
KR0131207B1 (ko) 1998-04-11
HU906229D0 (en) 1991-03-28
PT87380A (pt) 1988-05-01
CN1041054C (zh) 1998-12-09
CY1822A (en) 1995-10-20
US4910226A (en) 1990-03-20
EP0289327A3 (en) 1989-01-11
IL86185A0 (en) 1988-11-15
DK226888A (da) 1988-10-30
CN1030765A (zh) 1989-02-01
HUT47131A (en) 1989-01-30
CN1026236C (zh) 1994-10-19
NZ224377A (en) 1992-06-25
JPH0745511B2 (ja) 1995-05-17
EP0289327B1 (en) 1991-12-18
JPS6456694A (en) 1989-03-03
KR880012636A (ko) 1988-11-28
HK22695A (en) 1995-02-24
EP0289327A2 (en) 1988-11-02
ES2039278T3 (es) 1993-09-16
IE881269L (en) 1988-10-29

Similar Documents

Publication Publication Date Title
IL86185A0 (en) Steroid 5-alpha-reductase inhibitors
ZA883034B (en) Steroid 5-alpha-reductase inhibitors
DE3573429D1 (en) 17 beta-substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors
HU893412D0 (en) Inhibitors of interleucin-1
GB8707872D0 (en) Corrosion inhibitors
GR862032B (en) Dopamine-b-hydroxylase inhibitors
ZW21586A1 (en) Dopamine-b-hydroxylase inhibitors
ZW9087A1 (en) Dopamine-b-hydroxylase inhibitors
ZA934645B (en) 17-Alkylketone steroids useful as 5-alpha-reductase inhibitors
GB2173183B (en) Scale inhibitors
ZA889708B (en) 1-aralkyl-2 mercaptoimidazolines as dopamine-beta hydroxylase inhibitors
NZ193527A (en) Steroid salpha-reductase inhibitors
SG177994G (en) Steroid 5-alpha-reductase inhibitors
GB8504811D0 (en) Steroid compound
IL105527A0 (en) 17-beta-acyl-aromatic steroid 5-alpha-reductase inhibitors
IE872276L (en) DOPAMINE-ß-HYDROXYLASE INHIBITORS
ZA882479B (en) Use of a steroid
JPS6431743A (en) Triterpene compound
IE883247L (en) Sterol inhibitors of testosterone 5ó-reductase
MX9203759A (es) Inhibidores de 5-alfa-reductasa esteroidal.
IE881856L (en) Aromatase inhibitors
GB8506615D0 (en) Scale inhibitors
CS862387A1 (en) Smesny inhibitor koroze oceli
CS25787A1 (en) Inhibitor koroze
IE862056L (en) DOPAMINE-ß-HYDROXYLASE INHIBITORS